CPA
TXMD icon

Capital Performance Advisors’s TherapeuticsMD TXMD Stock Holding History

Capital Performance Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-600
Closed -$996 – 2515
2024
Q3 		$996 Buy
+600
New +$1.04K ﹤0.01% 1908

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Capital Performance Advisors's TXMD Position: Q4 2024 in Review

Capital Performance Advisors sold out of TherapeuticsMD (TXMD) in Q4 2024, closing a stake of 600 shares — an estimated $996 sold.

Capital Performance Advisors first reported a position in TXMD in Q3 2024 and held it in 1 quarter. The position peaked at $996 in Q3 2024. 41 funds tracked by Wall St. Rank hold TXMD as of Q4 2024.

  • Capital Performance Advisors reported no remaining TherapeuticsMD position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 600 TherapeuticsMD shares in Q4 2024, an estimated $996.
  • Capital Performance Advisors first reported a position in TherapeuticsMD in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's TherapeuticsMD position peaked at $996 in Q3 2024.
  • 41 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.